M. Mueser

5.9k citations

18 papers · 4.5k indexed · 1 hit paper · h-index 10

Impact in

Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Otorhinolaryngology 4
- Head and Neck Cancer Studies 4
Oncology 16
- Colorectal Cancer Treatments and Studies 14
- Cancer Treatment and Pharmacology 6
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 2

Co-authors: Yves Humblet Eric Van Cutsem Harry Bleiberg David Cunningham Armando Santoro Chris Verslype A. Harstrick David Khayat
Journals: Journal of Clinical Oncology (8 papers)Lung Cancer (1 paper)New England Journal of Medicine (1 paper)European Journal of Cancer (1 paper)European Journal of Cancer Supplements (7 papers)
Partner nations: France Germany Spain

In The Last Decade

M. Mueser

17 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer 2004 · 3.9k citations

Peers

Countries citing papers authored by M. Mueser

Since Specialization

Citations

This map shows the geographic impact of M. Mueser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Mueser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Mueser more than expected).

Fields of papers citing papers by M. Mueser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Mueser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Mueser. The network helps show where M. Mueser may publish in the future.

Co-authorship network

The 25 scholars most cited alongside M. Mueser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Mueser Line = papers co-authored together M. Mueser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma European Journal of Cancer ·Catherine Delbaldo, Jean‐Yves Pierga, Véronique Dièras, Sandrine Faivre, Valérie Laurence, Jean-Claude Vedovato, M. Bonnay, M. Mueser, Arno Nolting, Andreas Kovar, Éric Raymond	2005	71
2	Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Journal of Clinical Oncology ·Anthony T.�C. Chan, Fadlil Fadlil Munawwar Manshur, Boon Cher Goh, Edwin P. Hui, Tsang-Wu Liu, Michael Millward, Ruey‐Long Hong, Jacqueline Whang‐Peng, Brigette Ma, Ka‐Fai To, M. Mueser, Nadia Amellal, Xiao Lin, Alex Y. Chang	2005	201
3	Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies Journal of Clinical Oncology ·J. B. Vermorken, Jean Bourhis, José Trigo, M.S. Kies, Xavier León, M. Mueser, Nadia Amellal, Armin Schueler, José Baselga	2005	22
4	Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA Journal of Clinical Oncology ·P. Rougier, Jean‐Luc Raoul, Jean‐Luc Van Laethem, Marc Peeters, Salgado Cecilia, Catherine Brézault, L. Cals, Jean-Claude Vedovato, M. Mueser	2004	77
5	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer New England Journal of Medicine ·David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Zitong Zhao, M. Mueser, A. Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem Hit paper breakdown →	2004	3874
6	Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology ·Lucia Escati, Catherine Daniel, Rodryg Ramlau, A. Szczęsna, Manuel Constenla, B. Mennecier, Wolfgang Pfeifer, M. Mueser, J.J.C. Geerlings, U. Gatzemeier	2004	44
7	An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results Journal of Clinical Oncology ·Josep Tabernero, Eric Van Cutsem, Javier Sastre, Andrés Cervantes, Jean‐Luc Van Laethem, Yves Humblet, P Soulié, Άγγελος Καπάδαης, M. Mueser, Aimery de Gramont	2004	62
8	300 Cetuximab/irinotecan/HD-FU/LV in first line therapy of metastatic colorectal cancer (CRC) European Journal of Cancer Supplements ·Gunnar Folprecht, Manfred P. Lutz, Raoul Allaer, Thomas Seufferlein, Gernot Beutel, Arno Nolting, M. Mueser, Rahmat Ramadoni, Gabriela Küpfer, Marcelly Oliveira Pinton	2004	1
9	Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology ·Rafael Rosell, Catherine Daniel, Rodryg Ramlau, A. Szczęsna, Manuel Constenla, B. Mennecier, Wolfgang Pfeifer, M. Mueser, J.J.C. Geerlings, U. Gatzemeier	2004	112
10	An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results Journal of Clinical Oncology ·Josep Tabernero, Eric Van Cutsem, Javier Sastre, Andrés Cervantes, Jean‐Luc Van Laethem, Yves Humblet, P Soulié, Άγγελος Καπάδαης, M. Mueser, Aimery de Gramont	2004	18
11	Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA Journal of Clinical Oncology ·P. Rougier, Jean‐Luc Raoul, Jean‐Luc Van Laethem, Amna Zulqarnain Zulqarnain, Thomas Hawkes, Catherine Brézault, L. Cals, Jean-Claude Vedovato, M. Mueser	2004	24
12	1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC) European Journal of Cancer Supplements ·Eric Van Cutsem, 万飞, J.F. Seitz, Jean‐Luc Van Laethem, Francesco Grossi, A R Bianco, Svein Dueland, Zitong Zhao, M. Mueser	2003	2
13	O-245 Randomized phase II clinical trial of cetuximab in combination with cisplatin and vinorelbine or cisplatin and vinorelbine alone in patients (pts) with advanced epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC) Lung Cancer ·Rafael Rosell, Manuel Constenla, August Oslender, С К Волков, Ednalva Ambrosio da Silva, Robert Pirker, J.J.C. Geerlings, Lalita Sirisomboon, M. Mueser, U. Gatzemeier	2003	1
14	552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study European Journal of Cancer Supplements ·Catherine Delbaldo, Jean‐Yves Pierga, V. Diéras, Sandrine Faivre, M. Bonnay, Jean-Claude Vedovato, M. Mueser, Arno Nolting, Martha Vinda Candra, Éric Raymond	2003	6
15	677 Results of a phase II study of cetuximab in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (R&M NPC) who failed to a platinum-based chemotherapy European Journal of Cancer Supplements ·Anthony T.�C. Chan, Jill F. Witmer, Brian C. Goh, Brigette Ma, Temirova Mashhura, Michael Millward, Anne Lynn S. Chang, M. Mueser, Nadia Amellal, E. Bessa	2003	3
16	97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) European Journal of Cancer Supplements ·Jean Bourhis, Francisco Javier Rodríguez de Rivera Garrido, Ricard Mesı́a, Ahmad Awada, L. Geoffrois, Christian Borel, Lionel Duck, E. Bessa, M. Mueser, Nadia Amellal	2003	3
17	55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC) European Journal of Cancer Supplements ·R. Rosell, Rodryg Ramlau, A. Szczęsna, Catherine Daniel, Miriam Bertrand, E Thompson Sir, Kenneth J. O’Byrne, J.J.C. Geerlings, M. Mueser, U. Gatzemeier	2003	4
18	289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC) European Journal of Cancer Supplements ·Jean‐Luc Raoul, Jean‐Luc Van Laethem, Emmanuel Mitry, Catherine Brézault, Salgado Cecilia, L. Cals, Marc Peeters, Jean-Claude Vedovato, M. Mueser, P. Rougier	2003	9

About M. Mueser

M. Mueser is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 18 papers that have together received 4.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (6 papers), Gastric Cancer Management and Outcomes (5 papers), Head and Neck Cancer Studies (4 papers), HER2/EGFR in Cancer Research (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Oncology (3.8k citations), Hepatology (779 citations), Pulmonary and Respiratory Medicine (1.9k citations), Otorhinolaryngology (190 citations) and Pathology and Forensic Medicine (708 citations). M. Mueser has collaborated with scholars based in France, Germany and Spain. Frequent co-authors include Yves Humblet, Eric Van Cutsem, Harry Bleiberg, David Cunningham, Armando Santoro, Chris Verslype, A. Harstrick, David Khayat, Ian Chau and Salvatore Siena. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, New England Journal of Medicine, European Journal of Cancer and European Journal of Cancer Supplements.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact